Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus
Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus
复制标题
早期开始神经氨酸酶抑制剂治疗对甲型禽流感 (H7N9) 病毒住院患者的益处
DOI：
10.1093/cid/cix930
复制
发表时间：
2018-04-01
影响因子：
11.8
通讯作者：
Li, Lanjuan
中科院分区：
文献类型：
--
作者：
Zheng, Shufa;Tang, Lingling;Li, Lanjuan
背景早期神经氨酸酶抑制剂（NAI）治疗甲型流感（H7N9）的意义目前尚不清楚。2013年4月至2017年4月期间，浙江大学附属第一医院收治确诊H7N9感染的患者后，通过逆转录聚合酶链反应监测病毒脱落的持续时间。收集住院时间、病死率等指标，系统分析NAI给药时间与疾病严重程度的相关性。160例确诊H7N9感染患者按NAI开始时间分为3组。NAI治疗2天内死亡3例（15%），2-5天内死亡12例（23.1%），5天后死亡33例（37.5%）（P
Background. The significance of early neuraminidase inhibitor (NAI) therapy for treating influenza A(H7N9) is currently unknown.Methods. The duration of viral shedding was monitored by reverse-transcription polymerase chain reaction after patients with confirmed H7N9 infection were admitted to the First Affiliated Hospital, Zhejiang University, during April 2013-April 2017. Indices such as the length of hospitalization and mortality were collected, and the correlation between the time of administration of NAI and the severity of disease was systematically analyzed.Results. One hundred sixty patients with confirmed H7N9 infection were divided into 3 groups according to NAI starting time. Three of 20 (15%) patients for whom NAI was administered within 2 days died compared with 12 of 52 (23.1%) patients who received treatment within 2-5 days and 33 of 88 (37.5%) patients who were treated after 5 days (P